RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3

RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3

Source: 
Fierce Biotech
snippet: 

A phase 3 trial of RedHill Biopharma’s Crohn’s disease asset has met its primary endpoint. The study linked antibiotic cocktail RHB-104 to a higher rate of remission than placebo after 26 weeks, although the difference between the two arms shrunk later in the trial.